Form 4: Entrada Therapeutics Director Peter S. Kim Increases Stake in Company

Director Peter S. Kim of Entrada Therapeutics, Inc. (TRDA) acquired 1,512 shares of common stock at a weighted average price of $13.7526 on March 28, 2024.

Summary

• On March 28, 2024, Peter S. Kim, a director of Entrada Therapeutics, Inc., purchased 1,512 shares of the company's common stock.
• The shares were acquired at a weighted average price of $13.7526 per share.
• The transactions occurred in multiple purchases with prices ranging from $13.70 to $13.85.
• Following the reported transaction, Kim directly owns 60,336 shares of Entrada Therapeutics.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It reflects a routine transaction by a company director. While insider buying can be seen as a positive signal, it's a relatively small transaction and doesn't necessarily indicate a major shift in the company's outlook.

Positives

• A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track confidence levels and potential alignment of interests.

Stakeholder Impact

• The purchase could have a minor positive impact on shareholder sentiment.

Key Dates